MULTIPLE SCLEROSIS - DIAGNOSTIC AND THERAPEUTIC APPROACHES: A LITERATURE REVIEW
DOI:
https://doi.org/10.47820/recima21.v5i2.4950Keywords:
Multiple sclerosis. Diagnosis. TherapeuticsAbstract
Introduction: Multiple sclerosis (MS) is a progressive disease of the central nervous system with increasing global prevalence, representing a challenge for patients and health professionals. This study aims to address recent diagnostic and therapeutic strategies to improve the management of MS. Objective: To provide a comprehensive overview of diagnostic and therapeutic approaches to MS. Methods: A bibliographic review of the last 15 years was carried out in electronic databases, using specific inclusion criteria. Fifteen articles were selected after evaluating titles and abstracts. Results and Discussion: The increase in the incidence of MS globally and advances in diagnosis, including the role of magnetic resonance imaging and biomarkers, were highlighted. Conventional and emerging therapies were also addressed, emphasizing the importance of individualizing treatment and a multidisciplinary approach. Conclusion: Ongoing research and clinical trials are essential to fill knowledge gaps. A patient-centered approach, combined with scientific advances, promises to improve quality of life and clinical outcomes in MS.
Downloads
References
BAR-OR, Amit et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs, v. 74, p. 659-674, 2014. DOI: https://doi.org/10.1007/s40265-014-0212-x
BROWNLEE, Wallace J. et al. Diagnosis of multiple sclerosis: progress and challenges. The Lancet, v. 389, n. 10076, p. 1336-1346, 2017. DOI: https://doi.org/10.1016/S0140-6736(16)30959-X
CLAVELOU, Pierre. Can we optimize our teams? Multidisciplinary care for multiple sclerosis. Expert Review of Neurotherapeutics, v. 13, n. sup 2, p. 39-44, 2013. DOI: https://doi.org/10.1586/14737175.2013.865873
COHEN, Jeffrey A. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, v. 380, n. 9856, p. 1819-1828, 2012. DOI: https://doi.org/10.1016/S0140-6736(12)61769-3
COMABELLA, Manuel; MONTALBAN, Xavier. Body fluid biomarkers in multiple sclerosis. The Lancet Neurology, v. 13, n. 1, p. 113-126, 2014. DOI: https://doi.org/10.1016/S1474-4422(13)70233-3
DENNISON, Laura; MOSS-MORRIS, Rona; CHALDER, Trudie. A review of psychological correlates of adjustment in patients with multiple sclerosis. Clinical psychology review, v. 29, n. 2, p. 141-153, 2009. DOI: https://doi.org/10.1016/j.cpr.2008.12.001
DEVONSHIRE, V. et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis. European Journal of Neurology, v. 18, n. 1, p. 69-77, 2011. DOI: https://doi.org/10.1111/j.1468-1331.2010.03110.x
DOBSON, Ruth; GIOVANNONI, Gavin. Multiple sclerosis–a review. European journal of neurology, v. 26, n. 1, p. 27-40, 2019. DOI: https://doi.org/10.1111/ene.13819
EVANS, Charity et al. Adherence to disease‐modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiology and Drug Safety, v. 26, n. 6, p. 702-711, 2017. DOI: https://doi.org/10.1002/pds.4207
FEINSTEIN, Anthony et al. The link between multiple sclerosis and depression. Nature Reviews Neurology, v. 10, n. 9, p. 507-517, 2014. DOI: https://doi.org/10.1038/nrneurol.2014.139
FILIPPI, M.; PREZIOSA, P.; ROCCA, M. A. Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr Opin Neurol., v. 29, n. 3, p. 254-259, 2016.
FILIPPI, Massimo et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Archives of neurology, v. 68, n. 12, p. 1514-1520, 2011. DOI: https://doi.org/10.1001/archneurol.2011.914
FILIPPI, Massimo et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. The Lancet Neurology, v. 15, n. 3, p. 292-303, 2016. DOI: https://doi.org/10.1016/S1474-4422(15)00393-2
GALLIEN, Philippe et al. Multidisciplinary management of multiple sclerosis symptoms. European Neurology, v. 72, n. Suppl. 1, p. 20-25, 2014. DOI: https://doi.org/10.1159/000367620
GIOVANNONI, Gavin et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine, v. 362, n. 5, p. 416-426, 2010. DOI: https://doi.org/10.1056/NEJMoa0902533
GOLDENBERG, Marvin M. Multiple sclerosis review. Pharmacy and therapeutics, v. 37, n. 3, p. 175, 2012.
HAUSER, Stephen L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, v. 376, n. 3, p. 221-234, 2017. DOI: https://doi.org/10.1056/NEJMoa1601277
HAUSER, Stephen L.; CREE, Bruce AC. Treatment of multiple sclerosis: a review. The American journal of medicine, v. 133, n. 12, p. 1380-1390. e2, 2020. DOI: https://doi.org/10.1016/j.amjmed.2020.05.049
KALINCIK, Tomas. Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology, v. 44, n. 4, p. 199-214, 2015. DOI: https://doi.org/10.1159/000382130
LERAY, Emmanuelle et al. Epidemiology of multiple sclerosis. Revue neurologique, v. 172, n. 1, p. 3-13, 2016. DOI: https://doi.org/10.1016/j.neurol.2015.10.006
LIBERATORE, G. et al. Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. Multiple Sclerosis Journal, v. 20, n. 7, p. 862-870, 2014. DOI: https://doi.org/10.1177/1352458513508834
LUBLIN, Fred D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, v. 83, n. 3, p. 278-286, 2014.
MARRIE, Ruth Ann et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Multiple Sclerosis Journal, v. 21, n. 3, p. 305-317, 2015. DOI: https://doi.org/10.1177/1352458514564487
MCGINLEY, Marisa P.; GOLDSCHMIDT, Carolyn H.; RAE-GRANT, Alexander D. Diagnosis and treatment of multiple sclerosis: a review. Jama, v. 325, n. 8, p. 765-779, 2021. DOI: https://doi.org/10.1001/jama.2020.26858
MONTALBAN, Xavier et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine, v. 376, n. 3, p. 209-220, 2017. DOI: https://doi.org/10.1056/NEJMoa1606468
ONTANEDA, Daniel; FOX, Robert J.; CHATAWAY, Jeremy. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. The Lancet Neurology, v. 14, n. 2, p. 208-223, 2015. DOI: https://doi.org/10.1016/S1474-4422(14)70264-9
PAGNINI, Francesco et al. Symptom changes in multiple sclerosis following psychological interventions: a systematic review. BMC neurology, v. 14, n. 1, p. 1-9, 2014. DOI: https://doi.org/10.1186/s12883-014-0222-z
PAPEIX, Caroline et al. Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study. Multiple Sclerosis Journal–Experimental, Translational and Clinical, v. 1, p. 2055217315608864, 2015. DOI: https://doi.org/10.1177/2055217315608864
POLMAN, Chris H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology, v. 69, n. 2, p. 292-302, 2011. DOI: https://doi.org/10.1002/ana.22366
RIETBERG, Marc B. et al. Effects of multidisciplinary rehabilitation on chronic fatigue in multiple sclerosis: a randomized controlled trial. PloS one, v. 9, n. 9, p. e107710, 2014. DOI: https://doi.org/10.1371/journal.pone.0107710
RÍO, Jordi; COMABELLA, Manuel; MONTALBAN, Xavier. Multiple sclerosis: current treatment algorithms. Current opinion in neurology, v. 24, n. 3, p. 230-237, 2011. DOI: https://doi.org/10.1097/WCO.0b013e328346bf66
THOMPSON, Alan J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, v. 17, n. 2, p. 162-173, 2018. DOI: https://doi.org/10.1016/S1474-4422(18)30168-6
TINTORE, Mar; VIDAL-JORDANA, Angela; SASTRE-GARRIGA, Jaume. Treatment of multiple sclerosis—success from bench to bedside. Nature Reviews Neurology, v. 15, n. 1, p. 53-58, 2019. DOI: https://doi.org/10.1038/s41582-018-0082-z
WALLIN, Mitchell T. et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology, v. 92, n. 10, p. e1029-e1040, 2019.
WATTJES, Mike P. et al. MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. The Lancet Neurology, v. 20, n. 8, p. 653-670, 2021. DOI: https://doi.org/10.1016/S1474-4422(21)00095-8
WATTJES, Mike P.; RAAB, Peter. Brain and spinal cord MRI in multiple sclerosis: an update. Neurology International Open, v. 1, n. 04, p. E294-E306, 2017 DOI: https://doi.org/10.1055/s-0043-118111
WILSKI, Maciej et al. Psychological factors associated with self‐management in multiple sclerosis. Acta Neurologica Scandinavica, v. 142, n. 1, p. 50-57, 2020. DOI: https://doi.org/10.1111/ane.13236
ZIEMSSEN, Tjalf et al. Optimizing treatment success in multiple sclerosis. Journal of neurology, v. 263, p. 1053-1065, 2016. DOI: https://doi.org/10.1007/s00415-015-7986-y
Downloads
Published
How to Cite
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
